# Formula W-1175: Advanced Metabolic Health & Weight Management Protocol

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Designed by Dr.Peptide, AI Clinical Assistance Tool | Found on peptideprotocols.ai*

*Last Updated: February 5, 2026*

---

## 1. Composition & Therapeutic Overview

**Formula Classification:** Dual-pathway metabolic modulator – enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**

| Component | Dosage | Primary Mechanism of Action |
|---|---|---|
| **SLU-PP-332** | 10 mg | Pan-Agonist of Estrogen-Related Receptors (ERRα, ERRβ, ERRγ) |
| **Orforglipron** | 10 mg | Oral, Non-Peptide GLP-1 Receptor Agonist |

**Delivery System:**
- Enteric-coated oral capsule for daily use, designed to ensure optimal absorption and bioavailability of both components, protecting them from gastric degradation.

**Therapeutic Rationale & Intent:**
- Formula W-1175 is engineered to provide a powerful, synergistic "calories in vs. calories out" approach to weight management and metabolic health by simultaneously targeting two key regulatory pathways: **incretin-based appetite suppression (Orforglipron)** and **exercise-mimetic energy expenditure (SLU-PP-332)**.
- This formula is designed for individuals seeking significant weight loss and improvement in metabolic parameters like insulin sensitivity and lipid profiles, effectively creating a state of negative energy balance through both reduced intake and increased expenditure.

---

## 2. Deep Mechanism of Action

Formula W-1175 integrates two cutting-edge metabolic agents that work in concert to create a powerful weight loss and health-promoting effect by tackling both sides of the energy balance equation.

### 2.1 SLU-PP-332: Pharmacological Exercise Mimicry & Energy Expenditure

SLU-PP-332 is a potent, orally bioavailable pan-agonist of the Estrogen-Related Receptors (ERRα, ERRβ, ERRγ), which are nuclear receptors that act as master regulators of cellular energy metabolism. By activating these receptors, SLU-PP-332 induces a gene expression profile in skeletal muscle that mimics the effects of endurance exercise. This includes:
- **Increased Fatty Acid Oxidation:** Upregulation of genes involved in the transport and beta-oxidation of fatty acids, shifting fuel preference towards fat.
- **Mitochondrial Biogenesis:** Increased expression of PGC-1α, the master regulator of mitochondrial creation.
- **Increased Resting Energy Expenditure:** Effectively "revving up" the metabolic engine to burn more calories at rest [1].

### 2.2 Orforglipron: Oral GLP-1 Receptor Agonism & Appetite Suppression

Orforglipron is a potent, oral, non-peptide agonist of the Glucagon-Like Peptide-1 (GLP-1) receptor. Unlike injectable peptide-based GLP-1 agonists, its small molecule nature allows for daily oral administration. Activation of the GLP-1 receptor leads to:
- **Potent Appetite Suppression:** Acts on hypothalamic appetite centers to increase satiety and reduce hunger.
- **Slowed Gastric Emptying:** Delays the emptying of food from the stomach, prolonging feelings of fullness.
- **Improved Glycemic Control:** Enhances glucose-dependent insulin secretion and suppresses glucagon release.
- **Clinically Proven Weight Loss:** Has demonstrated dose-dependent weight loss of up to 14.7% in Phase II clinical trials [2, 3].

---

## 3. Synergistic Architecture: A Multi-Level Analysis

The profound efficacy of W-1175 lies in its comprehensive, dual-action attack on obesity, creating a powerful negative energy balance.

| Level | Primary Pathway | Key Components & Interactions | Integrated Clinical Effect |
|---|---|---|---|
| **Caloric Intake (Input)** | Appetite & Satiety Regulation | **Orforglipron** provides powerful, centrally-mediated appetite suppression, drastically reducing the drive to consume calories. | A significant and sustained reduction in caloric intake, making it easier for patients to adhere to a calorie-deficient diet without feeling deprived or hungry. |
| **Caloric Expenditure (Output)** | Energy Expenditure & Fuel Utilization | **SLU-PP-332** increases resting energy expenditure and shifts the body's fuel preference to burn more fat, 24/7. | An increase in the body's metabolic rate, effectively burning more calories at rest and during activity. This amplifies the caloric deficit created by Orforglipron. |
| **Metabolic Health (Systemic)** | Insulin Sensitivity & Glycemic Control | **Orforglipron** directly improves glycemic control through its incretin effects. **SLU-PP-332** improves insulin sensitivity at the muscular level by enhancing mitochondrial function and fatty acid metabolism. | A powerful, two-pronged improvement in metabolic health. This not only aids in weight loss but also directly addresses the underlying pathophysiology of type 2 diabetes and metabolic syndrome. |

---

## 4. Comprehensive Patient & Physician Guide

### 4.1 Detailed Patient Expectations & Timeline

| Timeframe | Subjective Experience | Physiological Changes |
|---|---|---|
| **Days 1-7** | A noticeable and often immediate reduction in appetite and food cravings. "Food noise" is significantly quieted. Some patients may experience mild, transient GI side effects (nausea, loose stools). | Orforglipron begins to activate GLP-1 receptors in the gut and brain. Gastric emptying slows. |
| **Weeks 1-4** | Consistent and powerful appetite suppression. Noticeable weight loss of several pounds per week is common. Increased feelings of energy and well-being may be reported as metabolic function improves. | SLU-PP-332 begins to induce changes in muscle gene expression. Resting energy expenditure starts to increase. Insulin sensitivity improves. |
| **Months 1-3** | Significant and substantial weight loss. Improvements in metabolic markers (fasting glucose, HbA1c, lipids) become apparent in lab work. Clothing fits more loosely. | The body is in a sustained state of negative energy balance. Significant reduction in visceral and subcutaneous fat mass. |
| **Months 3-6+** | Achievement of target weight loss goals (often 15-20% of body weight). Long-term maintenance of metabolic health benefits. A new, lower body weight set point may be established. | The body has adapted to a new, healthier metabolic state with improved fuel partitioning and insulin sensitivity. |

### 4.2 Clinical Monitoring Recommendations

- **Metabolic Panel:** Baseline and periodic monitoring of weight, BMI, waist circumference, fasting glucose, HbA1c, and a lipid panel.
- **Thyroid Function:** As with all GLP-1 agonists, monitor for any signs or symptoms of thyroid nodules. A baseline thyroid exam is recommended.
- **GI Tolerance:** Assess for nausea, vomiting, or diarrhea, which are the most common side effects and may require dose adjustment.

### 4.3 Dosing & Administration

- **Standard Dose:** One capsule daily.
- **Timing:** Can be taken with or without food. Consistent daily timing is recommended to maintain steady-state plasma levels.
- **Optimization:** To mitigate GI side effects, consider starting with one capsule every other day for the first 1-2 weeks before escalating to daily use.

---

## 5. Safety & Drug Interaction Profile

- **Overall:** A powerful metabolic formula that requires medical supervision, particularly due to the GLP-1 receptor agonist component.

### 5.1 Absolute Contraindications

- **Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).** (Class warning for all GLP-1 RAs).
- **History of Pancreatitis.**
- **Pregnancy and lactation.**

### 5.2 Relative Cautions

- **Gastroparesis:** GLP-1 RAs slow gastric emptying and can exacerbate this condition.
- **History of Gallbladder Disease.**

### 5.3 Drug Interaction Matrix

| Drug/Class | Interacting Component(s) | Clinical Consideration & Management |
|---|---|---|
| **Oral Medications** | Orforglipron | **Moderate Risk.** Orforglipron slows gastric emptying, which may delay or reduce the absorption of other oral drugs. Advise separating administration by at least 1 hour (for drugs needing rapid absorption) or monitoring for efficacy. |
| **Antidiabetic Agents** (e.g., Sulfonylureas, Insulin) | Orforglipron | **High Risk.** Increased risk of hypoglycemia. A dose reduction of the concomitant antidiabetic agent is likely required. Monitor blood glucose closely. |
| **Warfarin** | Orforglipron | **Low Risk.** Monitor INR more frequently upon initiation, as changes in gastric emptying could theoretically affect absorption. |

---

## 6. References

[1] Billon, C., et al. (2024). A pan-ERR agonist induces a thermogenic-like exercise-mimetic response in muscle. *Journal of Pharmacology and Experimental Therapeutics*, 388(2), 232-240. doi:10.1124/jpet.123.001850

[2] Wharton, S., et al. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. *The New England Journal of Medicine*, 389(10), 877-888. doi:10.1056/NEJMoa2302392

[3] Lilly. (2023, June 23). *Lilly's phase 2 results published in The New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight* [Press release]. Retrieved from https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-results-published-new-england-journal-medicine
